February 14, 2014 Actelion announced today that SwissMedic has approved Opsumit® (macitentan) for PAH patients within Switzerland. Opsumit is indicated for the long-term treatment of …
-
-
[[Whitepaper ]] Disruptive Innovation in Rare Disease Markets
-
Choosing the Right Channel Strategy for Specialty Product Success
-
[Whitepaper] Challenging Conventional Patient Recruitment and Care Strategies for Rare Disease Studies
-
[[whitepaper]] The New Reality: Maximizing Value in Rare Disease Launches
-
What’s New in Rare Cancer Research? (Spoiler Alert: A Lot!)
